An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 6, 2014, Pages 889-897

  Gion, Massimo ^a   Franceschini, Roberta ^a   Rosin, Claudia ^a   Trevisiol, Chiara ^b   Peloso, Lucia ^a   Zappa, Marco ^c   Fabricio, Aline S C ^a  

^a Ospedale Civile   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

Author keywords

Appropriateness; Epidemiology; Inappropriate tumor marker requesting; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; TUMOR ANTIGEN;

ARTICLE; BILIARY TRACT CANCER; BREAST CARCINOMA; ENDOMETRIUM CANCER; EPIDEMIOLOGICAL DATA; GALLBLADDER CANCER; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OVARY CANCER; PANCREAS CANCER; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RELATIVE; INFORMATION PROCESSING; MEDICAL ERROR; NEOPLASMS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; DATA COLLECTION; HUMANS; MEDICAL ERRORS; MODELS, STATISTICAL; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 84903598118     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0708     Document Type: Article

References (43)

1. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-e79. (Pubitemid 352777353)
2. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-e48.
3. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327. (Pubitemid 46631379)
4. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312. (Pubitemid 350232263)
5. Gion M, Rampazzo A, Mione R, Bruscagnin G. Cost/ effectiveness ratio of carcinoembryonic antigen - importance of adequacy of routine requests of tumour markers. Int J Biol Markers 1992;7:179-188.
6. Arioli D, Pipino M, Boldrini E, Amateis E, Cristani A, Ventura P, et al. Tumour markers in internal medicine: a low-cost test or an unnecessary expense? A retrospective study based on appropriateness. Intern Emerg Med 2007;2:88-94.
7. McDonnell M; Northern Ireland Regional Audit Group. An audit of tumour marker requests in Northern Ireland. Ann Clin Biochem 2004;41:378-384. (Pubitemid 39279923)
8. Ntaios G, Hatzitolios A, Chatzinikolaou A, Karalazou P, Savopoulos C, Karamouzis M, et al. An audit of tumour marker utilization in Greece. Eur J Intern Med 2009;20:e66-e69.
9. Walker PL, Crook M. Tumour marker requesting in primary care and the role of the laboratory. J Clin Pathol 2011;64:443-446.
10. Jackson BR. The dangers of false-positive and false-negative test results: false-positive results as a function of pretest probability. Clin Lab Med 2008;28:305-319. (Pubitemid 351626238)
11. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007;1:1-48.
12. Gion M, Barioli P, Ponti A, Torri V, Mione R, Dittadi R. How tumor markers are used in the routine follow-up of breast and colorectal cancer. A survey of 29 Italian hospitals. Int J Biol Markers 1998;13:124-38. (Pubitemid 29092521)
13. Gion M, Barioli P, Ponti A, Torri V, Mione R, Dittadi R. How CA 125 is used in the routine follow-up of ovarian cancer: a survey of 29 Italian hospitals. Tumour Biol 1998;19:269-274. (Pubitemid 28318437)
14. Franceschini R, Trevisiol C, Dittadi R, Gion M. Tumour markers requesting pattern with regards to different organizational settings in Italy: a survey of hospital laboratories. Ann Clin Biochem 2009;46:316-321.
15. Associazione Italiana di Oncologia Medica (AIOM). Linee guida neoplasie della mammella. Milano: AIOM, 2009.
16. Cardoso F, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20:15-18.
17. Associazione Italiana di Oncologia Medica (AIOM). Linee guida carcinoma del pancreas esocrino. Milano: AIOM, 2009.
18. Cascinu S, Jelic S. Pancreatic cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20:37-40.
19. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Pancreatic adenocarcinoma. Version 1.2009. Washington, PA: NCCN, 2009.
20. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Version 1.2010. Washington, PA: NCCN, 2009.
21. American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin. Management of adnexal masses. Obstet Gynecol 2007;110:201-214.
22. Associazione Italiana di Oncologia Medica (AIOM). Linee guida carcinoma dell'ovaio. Milano: AIOM, 2008.
23. Aebi S, Castiglione M. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20:21-23.
24. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Ovarian cancer. Version 2.2009. Washington, PA: NCCN, 2009.
25. Scottish Intercollegiate Guidelines Network (SIGN). Epithelial ovarian cancer. A national clinical guideline. Guideline n.75. Edinburgh: SIGN, 2003 - update 2007.
26. American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005;106:413-425.
27. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Uterine neoplasms. Version 1.2010. Washington, PA: NCCN, 2009.
28. Hospital bed-places by region: time series. Noi Italia: 100 statistics to understand the country we live in, 5th ed. ISTAT, Italian National Institute of Statistics. Available from: http://noi-italia.istat.it/. Accessed September 19, 2012.
29. AIRTUM ITACAN: cancer in Italy, Version 1. Italian Association of Cancer Registries. Available from: http://itacan.ispo.toscana.it/. Accessed September 19, 2012.
30. AIRTUM working group. Italian cancer figures, report 2010: cancer prevalence in Italy; Patients living with cancer, long-term survivors and cured patients. Epidem Prev 2010;34(Suppl 2): S1-S188.
31. Borgfeldt C, Andolf E. Transvaginal sonographic ovarian findings in a random sample of women 25-40 years old. Ultrasound Obstet Gynecol 1999;13:345-350. (Pubitemid 29312644)
32. Castillo G, Alcázar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 2004;92:965-969. (Pubitemid 38251403)
33. Gion M, Trevisiol C, Pregno S, Pinto C, Fabricio AS, editors. Guida all'uso clinico dei biomarcatori in oncologia 2010. Milano: Biomedia, 2010.
34. I tumori in Italia, il portale dell'epidemiologia oncologica. Istituto dei Tumori di Milano. Available from: http://www.tumori.net/. Accessed September 19, 2012.
35. Price CP. Evidence-based laboratory medicine: supporting decision-making. Clin Chem 2000;46:1041-1050. (Pubitemid 30643303)
36. De Laine KM, White GH, Koczwara B. Requesting biochemical tumor markers: a costly gap between evidence and practice? Asia-Pacific J Clin Oncol 2008;4:157-160.
37. Yilmaz G, Yilmaz FM, Senes M, Yucel D. TM requests in a general teaching Turkish hospital. Indian J Clin Biochem 2007;22:52-6. (Pubitemid 46411200)
38. Kwok J, Jones B. Unnecessary repeat requesting of tests: an audit in a government hospital immunology laboratory. J Clin Pathol 2005;58:457-462. (Pubitemid 40646864)
39. Loi S, Haydon AM, Shapiro J, Schwarz MA, Schneider HG. Towards evidence-based use of serum tumour marker requests: an audit of use in a tertiary hospital. Intern Med J 2004;34:545-550. (Pubitemid 39482329)
40. McGinley PJ, Kilpatrick ES. Tumour markers: their use and misuse by clinicians. Ann Clin Biochem 2003;40:643-647. (Pubitemid 37421709)
41. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
42. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 2002;48:1151-1159. (Pubitemid 34809819)
43. Sturgeon CM. Tumor markers in the laboratory: closing the guideline-practice gap. Clin Biochem 2001;34:353-359. (Pubitemid 32777842)